According to a systematic review and network meta-analysis by Gupta et al of randomized trials in hidradenitis suppurativa (HS), monotherapy with infliximab, bimekizumab, onabotulinumtoxinA, or oral tetracycline is more efficacious than placebo in reducing pain, inducing clinical response, improving quality of life, and lowering of abscess count, respectively.
“We determined the relative efficacy of nonsurgical monotherapies for [HS],” explained the study authors.
Researchers conducted a systematic review and network meta-analysis of randomized trials to rank their treatment efficacy using the cumulative ranking curve (SUCRA) value.
Infliximab had the highest SUCRA score for pain reduction compared with bermekimab, anakinra, and placebo. Bimekizumab had the highest SUCRA relative to adalimumab, anakinra, and placebo for occurrence of clinical response. OnabotulinumtoxinA had the highest SUCRA compared with adalimumab and placebo for quality of life in mild HS. Oral tetracycline had the highest SUCRA (48%) compared with topical clindamycin and vehicle for reduction in abscess count.
“Our work being the first [network meta-analysis] study on non-surgical HS monotherapies contributes to the comparative effectiveness literature for this condition,” concluded the study authors. –Lisa Kuhns
Reference
Gupta AK, Shear NH, Piguet V, Bamimore MA. Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. J Dermatolog Treat. Published May 7, 2021. doi:10.1080/09546634.2021.1927949
